 Patients with no local or metastatic disease progression will receive an additional two months of chemotherapy, followed by chemoradiation. Patients who have local disease progression will be switched to chemoradiation, undergo restaging assessment and be offered surgery in the absence of further disease progression. Patients with metastatic disease progression will be removed from the trial. Restaging imaging will be repeated four to six weeks after the completion of chemoradiation. In the absence of inoperable local disease progression or metastatic disease progression, patients will be offered surgical resection. Patients who received less than four months of neoadjuvant chemotherapy will receive four months of adjuvant chemotherapy. 